Inocras

Biotech & Life Sciences · United States · Founded 2020

Providing a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretations MoreLess

Inocras is an AI-driven company that specializes in delivering critical insights to cancer and rare disease patients through whole genome sequencing and bioinformatics. The company offers its whole genome testing products, CancerVision, RareVision and MRDVision, and provides research services for pharmaceutical and biotechnology companies as well as research organizations through its CAP/CLIA lab, powered by its proprietary, IP-protected bioinformatics pipeline. Inocras is dedicated to unlocking the potential of whole genome data to enable precision health for everyone.

Valuation $100–500M

Headcount <100

Total funding $50–100M

Unlock exact values

Company overview

Inocras company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2020
Headquarters: United States
Employees: 74
Open positions: None listed
Dealroom signal: 63.2

Website ↗LinkedIn ↗

sub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorDNAsectorGenetics and genomicssectorPrecision MedicinesectorDiseasesectorBiotech and PharmasectorHard TechsectorDT and LSsectorscience-basedclient focusb2b

Valuation & funding

Inocras funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jul 2025	$12M	$210M	Premier Partners · Forest Partners	—
SERIES BOther financing	Nov 2023	$23M	$190M	SIGNITE PARTNERS · Big Move Ventures · Samsung Ventures · DSC Investment	↗
SERIES BOther financing	Apr 2022	$23M	$65M	DSC Investment · KC · InterVest · Schmidt	↗
SERIES AOther financing	Nov 2020	$5.7M	$55M	Schmidt · Paratus Investment · DSC Investment	—
SEEDOther financing	Jan 2020	$300K	$3M	DSC Investment	↗

Showing 5 recorded eventsUnlock the complete deal history →

Growth signals

Inocras website traffic

Latest recorded traffic for Inocras is 11K monthly website visits, down 26.7% over the last three months. Inocras's team grew 8.8% over the past year.

Latest monthly visits11K 3-month web change-26.7% 1-year team growth+8.8%

Monthly website visits69 observations · Jul 2020–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Inocras compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DLDante LabsDante Labs is transforming genetics	New York City, United States	Operational	124	—	—
GEGeneYouInGeneYouIn (GYI), a Canadian personalized medicine company, has developed a genome analytics and reporting platform called PillCheck	Toronto, Canada	Operational
BABasgenbioVaszenio is a bio-vitator based on artificial intelligence that offers more than health value	Seoul, South Korea	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
PBPencil BiosciencesPencil Biosciences is a novel gene modulation company	Alderley Edge, United Kingdom	Operational
SOSolveBioSolveBio deploys technology and on-demand expertise to drive precision medicine We monitor, gather, and secure Genomic Intelligence	New York City, United States	Acquired
ACActXFocused on making patient genomic information that are useful in everyday medical practice	Seattle, United States	Operational
LILifebitEmpowers therapeutic leaders and pioneers in precision medicine on how to access and analyse siloed biomedical data	London, United Kingdom	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Inocras's talent

Book a demo to see the people

Team profiled 12 named & role-tagged

Founders /100 quality score

Key operators 8 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

15 investors on Inocras's cap table

Sourced from Dealroom's funding and investor records.

Seed 1 investor entered at this stage

DSC Investment

Series A 12 investors entered at this stage

Schmidt

Paratus Investment

Dunamu & Partners

InterVest

VNTG Corporation

Samsung Ventures

SIGNITE PARTNERS

Big Move Ventures

ASAN Foundation

Ignite Innovation

SCL Group

Series B+ 2 investors entered at this stage

Premier Partners

Forest Partners

Global footprint

Where Inocras has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States50%

🇰🇷 South Korea42.9%

🇭🇰 Hong Kong5.4%

🇬🇧 United Kingdom1.8%

4 countries shown

In the news

Latest news about Inocras

Recent press, funding announcements, and product moves mentioning Inocras — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Inocras

An AI-synthesized read of the highest-engagement posts about Inocras on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Inocras’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.